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HIV is characterized by the infection of CD4 T-cells and the accompanied attack of the 
immune system. Successful infection thus requires the binding to the CD4 receptor and 
a chemokine receptor, either CCR5 or CXCR4. In the early phase of infection the virus 
almost exclusively uses the CCR5-receptor. Only later during disease progression 
CXCR4-tropic viruses are found as majority in up to 50% of all patients. They associate 
with a more rapid CD4 T-cell loss and accelerated disease progression. The underlying 
causes of this change in the viral tropism are not known. As a significant percentage of 
patients only achieve a suboptimal CD4 T-cell recovery while treated, the viral tropism 
might play a role for such an incomplete immune response. The aim of this thesis was 
to follow the viral tropism dynamics, especially the abundance of CXCR4-tropic cell-
associated viruses during phases of immune recovery by combination antiretroviral 
therapy with the intention to understand and help improving the immune situation 
during therapy. Patient samples from the Swiss HIV Cohort Study were used to asses 
the viral tropism before and after several years of treatment initiation. As during 
therapy free plasma virus was fully suppressed, analysis focus laid on integrated viral 
genomes. This work found that CXCR4-tropic viral variants are not inevitably associated 
with an impaired CD4 T-cell recovery as most of the viruses with a pre-treatment 
CXCR4 tropism presented a CCR5-tropism during therapy. Furthermore, it identified 
that the frequency of CXCR4-tropic viruses under therapy generally decreases and that 
therefore the proviral reservoir mostly persists of CCR5-tropic viruses. Based on the 
fact that all free viral variants were equally suppressed these findings suggest the 
involvement of the immune system, which appears to selectively target CXCR4-tropic 
infected cells. If a competent immune system were capable of preferentially controlling 
CXCR4-tropic viruses, this would also explain why these variants mostly appear later 
during disease when the damage of the immune system is accelerated. As a 
consequence, the findings discussed in this thesis support early therapy initiation as 
strategy to prevent the later occurrence of CXCR4-tropic HIV. Furthermore, remaining 
CCR5-tropic viruses may most effectively be suppressed by additional therapy options 




























II. I. STATUS QUO ON HIV  
With currently around 36.9 million people infected and 1.2 million HIV related deaths 
by the end of 2014 the burden of HIV in the world is still huge1. Nevertheless, the 
tremendous efforts that have been undertaken and have led to 15 million patients 
treated with combination antiretroviral therapy (cART) by the year 20151 have to be 
acknowledged. These improvements are not only owed to a more reliable availability 
of diagnostic testing and drug distribution worldwide but also to one of the main 
focuses in recent years – treatment as prevention2. Prevention mainly includes pre-
exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) and cART for pregnant 
and breastfeeding women2. PrEP supports the daily intake of antiviral drugs for 
uninfected people at high risk for an infection and has been shown to protect against 
infection in different risk populations (e.g. serodiscordant couples or men who have sex 
with men (MSM))2-4. PEP includes the immediate intake of antivirals after exposure to 
HIV, protection against the establishment of an infection has been shown in studies 
including health care workers or victims of sexual assaults5-7. By the end of June the 
World Health Organization announced that Cuba, as one of the first countries 
worldwide, has eliminated mother-to-child transmission of HIV8. Together with other 
methods of prevention like male circumcision these all have contributed to prevent HIV 
transmission2. Despite these advances, however, the situation in developing countries, 
mainly in sub-Saharan Africa, looks different than in the Western countries. In 
Switzerland for example, data from 2012 show that over 90% of patients in care 
received cART and over 90% of those receiving cART were suppressed9. In contrast, a 
recently published survey from Kenya reported that only close to 40% of the enrolled 
patients received cART, and that of those also only 40% had a viral load (VL) below 
1000 copies/mL10. In terms of HIV care cascades efforts have to improve substantially. 
This is also the reason why the United Nations initiated the goal of 90-90-90 by 202011. 
Briefly, 90% of all infected people worldwide should know their status, 90% of them 
should have access to treatment, and 90% of these treated patients should be able to 
reach suppression11. While working towards this goal, which focuses more on the 
clinical side, the leading term now promoted on the research side is “eradication”. HIV 
eradication appears to be extremely difficult to achieve, and to date only one case is 
known worldwide where indeed HIV seems to be cleared from a patient. In this special 




transplantation due to his leukemia12. A donor was searched possessing the rather rare 
homozygous delta32 mutation (<1% in the Caucasian population13) in the gene coding 
for one of the co-receptors HIV needs to infect a cell. After successful bone marrow 
transplantation the patient was not only cured from leukemia but is now lacking any 
sign of HIV or infected cells for years12,14. Aside from the special circumstances that 
probably allowed for a cure in this single case of HIV, two main features make it so 
hard to reach a cure. First, HIV integrates its own genome into the host T-cell genome, 
and secondly reverse transcriptase lacks proof reading, which results in a massive viral 
variability that cannot be controlled by the immune system of the host15-17. Therefore, 
to date most strategies for eradication include either mechanisms to activate latent 
infected cells and kill them, to excise the HIV genome of the host genome, or to 
develop broadly neutralizing antibodies that can cope for a large variety of virus 
variants18-21. A huge effort lies in all these research fields to contribute to a cure of HIV 
infection that not yet seems reachable. Additional ideas and maybe also different ways 
of looking at known paradigms are needed to highlight possible new ways of HIV 
control. 
 
II.II. BACKGROUND ON HIV CO-RECEPTORS 
HIV infection depends on the binding of the virus to the cell surface receptor CD4 and, 
in addition, a chemokine receptor22. This “co-receptor” is in most cases either the 
CCR5 (R5) or the CXCR4 (X4) receptor23,24. “CCR5” stands for CC-motif chemokine 
receptor 5 and “CXCR4” for the CXC-motif chemokine receptor 425,26. Their names 
derive from the cysteine motif of the chemokine that can activate the receptor for 
signaling, both receptors belong to the family of the G-protein coupled receptors 
(GPCRs)24-26. The R5-receptor is stimulated by the chemokines MIP-1α (macrophage 
inflammatory protein-1α), MIP-1β (macrophage inflammatory protein-1β) and RANTES 
(regulated on activation, normal T-cell expressed and secreted), they all are involved in 
the attraction of leukocytes to sites of inflammation26. The ligands for the X4-receptor 
are SDF-1 (stromal derived factor-1) and MIF (macrophage migration inhibitory factor), 





FIGURE 1 Schematic drawing of the binding of the CD4 receptor to gp120 and the V3 loop to the co-receptor. A) 
Binding of gp120 to the CD4 receptor. B) The V3 region binds to the co-receptor. C) Gp41 provides fusion of HIV 
with the cell membrane. Abbreviations: gp120, glycoprotein 120; gp41, glycoprotein 41; V3, variable loop 3. 
 
FIGURE 1 Schematic drawing of receptor ligand interaction. 
II.III. CHARACTERISTICS OF HIV CO-RECEPTORS IN DISEASE 
HIV variants that infect cells via the R5-receptor (R5-tropic/R5-tropism) are macrophage 
tropic and are also called “non-syncytium inducing virus28,29. If, on the other hand, the 
virus uses the X4-receptor (X4-tropic/X4-tropism) it is either T-cell or macrophage 
tropic, and also called “syncytium inducing”28-30. A virus might also have the properties 
to infect a cell via both receptors (dual tropism), or there is furthermore the possibility 
that a host harbors different viruses that have different tropisms (mixed tropism)28. The 
most critical region in the HIV genome to bind to the co-receptor is called the variable 
loop 3 (V3) located in the glycoprotein 120 (gp120)31. A schematic drawing of how the 
virus binds to its receptor is shown in FIGURE 1. The V3 loop is generally 35 amino acids 
long, positions 11, 24, and 25 in the loop are especially critical as positively charged 
amino acids at these positions are strongly associated with an X4-tropism32. Also the 
loss of a glycosylation site within the loop is a determinant for X4-tropism33. It was 
recognized early that X4-tropic viruses tend to associate with a faster cell infection rate, 
show higher cytopathic effects, and induce extended cell fusion events (syncytia), 
whereas the R5-tropic viruses show slower progression rates and less cytopathology34. 
Therefore X4-tropic viruses were associated in many studies with an accelerated 
decline in CD4 T-cells and a faster disease progression35,36. However, whether X4-tropic 















Adapted from Moore et al. 200337 








Currently no drugs are approved for HIV therapy that target the X4-tropic viruses or 
the X4-receptor. There is, however, a drug on the marked called “maraviroc” that 
blocks the human R5-receptor38,39. Around one percent of the Caucasian population 
has a homozygous deletion in the gene coding for the R5-receptor, these individuals 
cannot be infected with an R5-tropic virus13. Additionally, up to 20% of this population 
have a heterozygous deletion that is associated with decelerated disease 
progression13,40. Blocking the R5-receptor, however, does not prevent the infection with 
X4-tropic viruses13. The consequences for the immune system if the R5-receptor is 
missing are not clear, however, it has been associated with a higher susceptibility to 
West-Nile Virus infection41,42. Maraviroc was approved only for the use on patients with 
R5-tropic viruses43, therefore testing systems to determine the “tropism” of HIV were 
needed. Test systems, like Geno2Pheno, were developed to determine the tropism via 
genotyping by using the sequence information of the V3 loop44. Another possibility to 
determine the tropism is via a hybridization based approach to a probe of known 
tropism, this technique was developed in our lab and is called XTrack45. 
 
II.IV. ROLE OF CHEMOKINE RECEPTORS IN HIV INFECTION 
Transmission of HIV mostly occurs through an R5-tropic virus46, and X4-tropic virus 
variants are only rarely found during the early stages of disease47,48. The reason for the 
selective infection advantage of R5-tropic viruses is not entirely clear up to date and is 
rather seen as interplay between different barriers49. For example, one of these barriers 
is the female genital tract, cervical tissue is known to express mainly the R5- and not 
the X4-receptor50. Another example is the presence of SDF-1 (ligand for the X4-
receptor) in the mucosal tissue that leads to a continuous down regulation of the X4-
receptor and may therefore prohibit infection via this route51. There are also reports 
that suggest a more readily elimination of X4-tropic variants by the neutralizing 
antibody response based on their fewer glycosylation sites and lack of the so called 
glycan shield, which protects R5-tropic variants better from the recognition of the 
immune system33,52-54. R5-tropic variants have been shown to have a selective escape 
advantage during chronic infection as the viruses were glycosylated at specific sites 
known to prohibit antibody recognition55. Although the early dominance of infection 
via the R5-receptor, in up to 50% of patients X4-tropic variants appear later in disease, 
and most important in the absence of treatment30,56,57. The underlying mechanisms of 




observations on an increase in X4-tropic viruses were observed in treatment free 
situations30,56,57. However, how the viral tropism behaves in a treated situation is not 
well studied. Although the emergence of X4-tropic variants associates with a faster 
disease progression35,36, the majority of patients still progress to immunodeficiency 
without showing an increase in X4-tropic variants58. Interestingly, there are studies that 
determined the viral tropism to identify patients eligible for R5-receptor antagonist 
treatment59,60. These patients were long-term treated, under a failing therapy regimen 
and the majority of them presented R5-tropic viruses at screening59,60. The exact 
contribution of the viral tropism, especially the X4-tropism, to the disease dynamics 
during antiviral therapy remains controversial. In the absence of clinically available X4-
receptor antagonists for directly targeting X4-tropic viruses a better understanding is 
needed of whether and how X4-tropic viruses contribute to the progression of the 
disease. 
 
II.V. LINK BETWEEN TROPISM AND CD4 T-CELL RESPONSE 
It has been reported that even patients under potent combination antiretroviral 
therapy and fully suppressed free virus experience suboptimal CD4 T-cell recovery61. 
Determinants for such a CD4 T-cell impairment during fully suppressive therapy have 
been studied, and only higher age at time of infection as well as an advanced disease 
stage at diagnosis have been identified as significant associates61. As therapy was 
successful and did not associate with the different CD4 T-cell outcome either, it may 
be suggested that other factors are involved, such as viral properties and/or the 
immune system of the host. Viral properties such as the tropism have not been 
addressed in this context, but are known to initiate different immune responses mainly 
based on their distinctive glycosylation patterns33,54,55. As X4-tropism is associated with 
disease progression and a more rapid CD4 T-cell loss35,36, it was the aim of this work to 
investigate the dynamics of the viral tropism during treatment and to address if the 

































III.I. TROPISM AND DISEASE PROGRESSION 
III.I.I. AIM OF THE STUDY 
HIV infection via chemokine receptor X4 correlates with faster disease progression, a 
more rapid decline in CD4 T-cells, and therefore earlier signs of AIDS related 
illnesses35,36. Furthermore, it has been clinically observed that in a substantial number 
of HIV infected individuals, even under suppressive cART, CD4 T-cell recovery is often 
not adequate61. The hypothesis is that this impaired CD4 T-cell response during 
therapy may associate with the viral tropism, considering that X4-tropism seems to 
associate with a poorer outcome of the disease35,36. The aim of this study was to 
substantiate a link between viral tropism and immunological outcome. 
 
III.I.II. STUDY DESIGN AND SAMPLE SELECTION 
To assess a possible association of viral tropism with immunological outcome patients 
from the Swiss HIV Cohort Study (SHCS) who had been under cART for more than five 
years and had no virological failure (VL during study period below 50 copies/mL) were 
included. Samples were grouped according to the increase in CD4 T-cells from therapy 
initiation (baseline, BL) to after five years on cART, into “responders” (n=44) with a 
delta above 400 CD4 T-cells or “incomplete responders” (n=44) where the CD4 T-cell 
delta remained below 400 cells. It was possible to choose a high CD4 T-cell delta since 
all patients were long-term infected and therefore had a low baseline CD4 T-cell count 
(median 174 cells/µL). Tropism analysis was performed on plasma near the time of 
cART initiation. All patients responded well to the antiviral treatment as all had a rapid 
viral load decline after cART initiation. Viral loads then remained below 50 copies/mL 
with no viral rebound for the entire study period (VL was routinely measured every 
quarter), which indicated that patients were adherent and the virus did not acquire 
resistances. cART was defined as a combination of at least three antiretroviral drugs, 
consisting of two nucleosidic reverse transcriptase inhibitors (NRTI) combined with 
either one or two protease inhibitors or with one non-nucleosidic reverse transcriptase 
inhibitor (NNRTI). None of the patients ever received CCR5 antagonists for therapy. 
For genotypic tropism determination Geno2Pheno (G2P; Max-Planck-Institute, 
Saarbrücken, Germany) and XTrack (InPheno AG, Basel, Switzerland) were used (see 




III.I.III. PATIENT CHARACTERISTICS 
The patient population (n=88) had a mean age of 54.5 ± 10.9 years, 76% were male 
and 90% were white, 49% were MSM. The mean duration of infection was 18.7 ± 4.7 
years 62, and 76% of the patients had started with cART prior to the year 2000. Baseline 
median CD4 T-cell count was 174 cells/µL, baseline CD8 cell count was 787 cells/µL, 
and baseline viral load was 5.0 log10 copies/mL. Based upon analysis at the follow-up 
time point 21% of the patients (17/81; seven were not analyzable) had a delta32 
heterozygous genotype, none was homozygous. 
In the incomplete responder group patients had overall initiated cART at a lower 
median CD4 T-cell count of 139 cells/μL vs. 220 cells/μL in the responder group 
(p=0.039). Thus, it was key to rule out a CD4-based bias in the findings. Therefore, a 
sub-analysis (n=38) of incomplete responders with high CD4 T-cell baseline count vs. 
complete responders with low CD4 T-cell baseline count was performed, indicating 
that a lower CD4 T-cell baseline count was not the primary cause of incomplete 
response (p=0.073). 
Median CD8 cell count at baseline for incomplete responders was 861 cells/μL vs. 764 
cells/μL (p=0.780) and median viral loads were 5.0 log10 copies/mL vs. 4.8 log10 
copies/mL (p=0.152). Demographic characteristics revealed a longer but not significant 
duration of infection62 for the incomplete responders with 19.6 vs. 17.8 years 
(p=0.106). The relative occurrence of a delta32 heterozygous genotype was similar in 
both groups (10 and 7 cases, respectively (p=0.446)). Baseline characteristics are 
summarized in TABLE 1. 
There was no statistically significant difference in the first line regimen between the two 















TABLE 1 Baseline characteristics for 88 HIV-1 infected, treatment-naïve patients. 
Data are presented as No. (%), median or IQR values unless otherwise indicated. Categorical data were compared 
by means of Chi-square test, whereas continuous data were compared by Mann-Whitney-Wilcoxon test. 
Abbreviations: SD, standard deviation; MSM, men who have sex with men; HET, heterosexual; IDU, injecting drug 











Incomplete                              
re  responders 
(n=44) 
P 
Sex           
    Male 67 (76.1)   30 (68.2) 37 (84.1)   0.080 
    Female 21 (23.9)   14 (31.8)   7 (15.9)     
Age, mean years ± SD 54.5 ± 10.9   52.1 ± 10.9 56.9 ± 10.5   0.019 
Ethnicity           0.239 
    White 79 (89.8)   39 (88.6) 40 (90.9)    
    Black   5 (5.7)     3 (6.8)   2 (4.6)     
    Hispanic   2 (2.3)     2 (4.6)       
    Asian   2 (2.3)        2 (4.6)     
HIV transmission            0.610 
    Blood   1 (1.1)     1 (2.3)      
    MSM 43 (48.9)   20 (45.5) 23 (52.3)     
    HET 31 (35.2)   17 (38.6) 14 (31.8)     
    IDU 11 (12.5)     6 (13.6)   5 (11.4)     
    Other   1 (1.1)       1 (2.3)     
    Not available   1 (1.1)       1 (2.3)     
Age at infection,  
    mean years ± SD 
36.1 ± 11.7   34.5 ± 12.4 38 ± 10.6   0.073 
Duration of infection, 
    mean years ± SD 
18.7 ± 4.7   17.8 ± 4.7 19.6 ± 4.7   0.106 
CDC Stage             
    C 24 (27.3)   12 (27.3) 12 (27.3)   1.000 
cART initiation             
    before 2000 67 (76.1)   32 (72.7) 35 (79.5)   0.453 
    after 2000 21 (23.9)   12 (27.3)   9 (20.5)     
Baseline HIV RNA load, 
    log10 copies/mL 
5.0 (4.3-5.3)   4.8 (4.2-5.2) 5.0 (4.5 -5.5)   0.152 
Delta CD4 T-cell count, 
    cells/µL 
399 (235-579)   579 (499-705) 235 (192-308)   0.001 
Baseline CD4 T-cell count, 
    cells/µL 
Baseline CD8 T-cell count, 










  0.039 
 
0.780 
Delta32 genotype             
    heterozygous 17 (21.0)   10 (24.4)   7 (17.5)   0.446 
    wild type 64 (79.0)   31 (75.6) 33 (82.5)     




III.I.IV. SAMPLE ANALYSIS  
A total of 88 baseline (BL) profiles were available for comparison. Overall 44 were 
responders and 44 were incomplete responders according to the patients’ delta CD4 
T-cell count after five years of follow-up. Eighty-one of the 88 samples (92%) had 
concordant results between G2P and XTrack. 
 
III.I.V. CD4-RESPONSE - CORRELATING BASELINE TROPISM WITH IMMUNOLOGICAL OUTCOME 
The mean timespan between baseline analysis and time point of follow-up was 5.2 ± 
0.6 years. For 84 patients a tropism assignment was successful using the online tool 
G2P. The “False Positive Rate” cutoff was set to 5%. For four patients G2P yielded no 
result due to the presence of a mixed virus population. This is the case when the 
sequencing electropherogram shows peaks that mask each other and give no clear 
result at a given position. G2P predicted 69 patients (82.1%) to carry an R5-tropic virus 
and 15 (17.9%) to carry an X4-tropic virus, considering that 88% of samples had 
subtype B determined by G2P. 60% of the patients (9/15) with X4-tropic viruses and 
46.4% (32/69) with R5-tropic viruses were in the incomplete responder group 
(p=0.339). Data are shown TABLE 2. In addition, XTrack assigned mixed virus 
populations in a given specimen. In the incomplete responder group 42% of the 
patients (21/50) harbored R5-tropic viruses, 64% (16/25) a mixed virus population, and 
53.8% (7/13) X4-tropic viruses (p=0.190), as shown in TABLE 2. 
 
TABLE 2 Tropism analysis at baseline for 88 HIV-1 infected, treatment naïve patients. 












Geno2Pheno (FPR 5%)           
   R5-tropic 69 (82.1)   37 (86.0) 32 (78.0)   0.339 
   X4-tropic 15 (17.9)   6 (14.0) 9 (22.0)    
Geno2Pheno (FPR 10%)         
   R5-tropic 65 (77.4)   34 (79.1) 31 (75.6)   0.705 
   X4-tropic 19 (22.6)   9 (20.9) 10 (24.4)    
    













XTrack         
    R5-tropic 50 (56.8)   29 (65.9) 21 (47.7)   0.190 
    X4-tropic 13 (14.8)   6 (13.6) 7 (15.9)    
    Mixed tropic 25 (28.4)   9 (20.5)  16 (36.4)    




FIGURE 2 G2P tropism analysis for the 17 patients with a heterozygous delta32 
genotype. Abbreviations: R5, R5-tropic HIV; Mix, mixed sequence; X4, X4-tropic HIV. 
 
FIGURE 2 Tropism distribution for patients with heterozygous delta32 genotype. 
III.I.VI. CONTRIBUTION OF THE DELTA32 GENOTYPE 
According to G2P of the analyzed 17 patients (21%) with a heterozygous delta32 
genotype two (11.8%) had a mixed viral sequence, nine (52.9%) had an R5-tropism and 
six (35.3%) an X4-tropism at baseline (see FIGURE 2). The portion of X4-tropic viruses in 
this subpopulation of patients with a delta32 genotype was higher than in the general 
patient population (p=0.0135), but patients with R5-tropic viruses still accounted for 





























III.II. PREFERENTIAL SUPPRESSION OF CXCR4-TROPIC HIV-1 UNDER CART 
III.II.I. AIM OF THE STUDY 
In the previous study a possible association of tropism and immunological outcome 
was assessed. As the tropism determination was years before the impaired CD4 T-cell 
recovery was established and X4-tropic variants did not significantly associate with this 
impairment, a subsequent study was needed to assess the tropism in the proviral 
reservoir at the time point where the CD4 T-cell impairment was established. Aim of 
this subsequent study was to compare the tropism determination in free plasma virus 
with provirus over time and to investigate if the viral tropism is constant during therapy. 
 
III.II.II. STUDY DESIGN AND SAMPLE SELECTION 
To study the tropism dynamics during the time of therapy the same study population 
as described in chapters III.I.III and TABLE 1 was used. Since all patients were under 
successful treatment they had no free virus in the plasma, rendering its analysis at this 
later time point during therapy impossible. Therefore, tropism analysis had to be done 
from integrated virus (provirus) on peripheral blood mononuclear cells (PBMC). The 
sample set was extended by inclusion of PBMC samples from the same patients at the 
time point they had been on treatment for five years. This was the same time point 
from which also the data on CD4 T-cell counts for grouping of the patients in the first 
study stemmed. It was assumed that a bias would be introduced by comparing data 
from plasma at baseline and PBMCs at follow-up. Therefore, also PBMC samples from 
the baseline time point were included to compare the viral tropism in the different 
compartments. Genotypic tropism determination was again performed with 
Geno2Pheno (Max-Planck-Institute, Saarbrücken, Germany) and XTrack (InPheno AG, 
Basel, Switzerland) (see Methods for more details). 
 
III.II.III. SAMPLE ANALYSIS 
Corresponding baseline data sets of plasma virus (PL) and provirus (PBMC) were 
available for 39 patients. Tropism analysis with G2P was largely concordant for virus 
and provirus at baseline in 90% of them (35/39). In order to follow a possible evolution 
of the viral tropism from before therapy to five years after therapy initiation, proviral 
tropism data from PBMCs at baseline (BL-PBMC) were compared with tropism data 




FIGURE 3 Distribution of the samples between different compartments and time points. 
Abbreviations: BL, baseline; PBMC, peripheral blood mononuclear cells; 5Y, after five 
years of therapy. 
 
data from the five year follow-up PBMC samples (5Y-PBMC) were compared with the 


















III.II.IV. PROVIRAL TROPISM AT BASELINE AND ITS EVOLUTION AFTER FIVE YEARS OF THERAPY 
For the comparison of proviral deoxyribonucleic acid (DNA) in PBMC at baseline and 
five years after (BL-PBMC/5Y-PBMC) a complete data set (G2P and XTrack) was 
available from 50 patients. Five patients had no G2P result due to mixed viral 
sequences and one had no XTrack result due to an inconclusive result. With 39 of 45 
analyzed samples (86.7%), the majority of patients carried R5-tropic viruses at baseline. 
Thirty-three of these 39 patients (84.6%) still had an R5-tropic virus at follow-up, and in 
the remaining six patients the viral tropism had changed to X4. Of the six patients with 
X4-tropic virus at baseline, four (66.7%) had changed to R5-tropism at follow-up. G2P 
data are summarized in FIGURE 4A. 
The XTrack analysis was used to address especially mixed virus populations: Among 
the 28 patients with initially R5-tropic HIV, four cases (14.3%) presented a mixed virus 
population at follow-up. Among the nine patients with a mixed population at baseline, 
the mixed tropism remained stable in two cases (22.2%) after 5 years. A tropism 
change to R5 occurred in four patients (44.5%), and in three cases (33.3%) the later 




samples revealed solely X4-tropic virus. For the 12 patients with X4-tropic virus at 















III.II.V. TROPISM IN PLASMA VIRUS AT BASELINE AND COMPARISON TO PROVIRAL TROPISM AFTER 
FIVE YEARS OF THERAPY 
In the data set, 61 patients had a G2P and XTrack baseline plasma tropism result 
available as well as a corresponding follow-up proviral tropism result from PBMC. The 
comparison of the two different compartments was possible due to the observed good 
concordance of 90% between plasma and PBMC samples at baseline (see chapter 
III.I.IV). Six had again no G2P result due to mixed viral sequences, and one had no 
XTrack result due to inconclusive results. At baseline R5-tropic viruses were identified 
in 47 of the remaining 55 patient samples (85.5%), of which 40 (85.1%) were still R5-
tropic at follow-up. Among the eight X4-tropic virus samples at baseline the tropism 
had changed in six patients (75%) to R5 at follow-up. G2P data are summarized in 
FIGURE 4B. XTrack was again used to examine mixed virus populations, among the 36 
R5-tropic samples (60%) from baseline, four (11.1%) changed to a mixed population. 
For 17 patients with a mixed virus population at baseline, HIV changed to become R5-
B 
FIGURE 4 G2P analyzed tropism changes during therapy. 
A B 
! RESULTS 
FIGURE 4 Geno2Pheno analysis between compartments and time points. Geno2Pheno (FPR 
5%) results comparing tropism between (A) the proviral compartments (n=45) and (B) free 
virus (plasma) at baseline with provirus (n=55) after five years of therapy for patients with R5- 
(left panel) or X4-tropic (right panel) HIV at baseline. Abbreviations: PBMC, peripheral blood 




tropic in nine cases (52.9%), two (11.8%) became X4-tropic, and in six (35.3%) cases the 
viral tropism remained mixed. Among the seven patients with an X4-tropic virus at 
baseline, one (14.3%) changed to a mixed population. The results are shown in FIGURE 
5B. 
Considering the excellent concordance observed between baseline plasma and PBMC 
samples (in 90% of all cases) the mean percentage of samples changing from an X4-
tropism at baseline to R5 at follow-up was calculated, regardless of the origin, plasma 
or PBMC. Thus in 70.9% of all samples with an X4-tropism at baseline the tropism 
changed to R5 at follow-up in the G2P analysis, whereas only 15.2% changed from R5 
to X4-tropism.  
 
 
















III.II.VI. BULK SEQUENCING ANALYSIS OF VIRUS ENVELOPES WITH TROPISM DIFFERENCES OVER TIME 
For the majority of X4-tropic viruses that presented an R5-tropism determination after 
five years several random nucleotide changes in the V3 loop sequence were observed. 
In contrast, for most R5-tropic viruses switching to X4-tropism, one or two nucleotide 
changes were sufficient to yield the X4-tropism. Most frequent were amino acid 
FIGURE 5 XTrack analyzed tropism changes during therapy. 
FIGURE 5 XTrack analysis between compartments and time points. XTrack results comparing 
tropism between (A) the proviral compartments (n=49) and (B) free virus (plasma) with provirus 
(n=60) after five years of therapy for patients with R5- (left panel), mixed- (middle panel) or X4-
tropic HIV (right panel) at baseline. Abbreviations: PBMC, peripheral blood mononuclear cell; 






FIGURE 6 AMINO ACID CHANGES IN THE V3 LOOP DURING THERAPY. 
changes from Serine (S), Glycine (G), or Glutamine (E) to Arginine (R). Those occurred 
at positions 11, 24, or 25 of the V3 loop. Also about half of the affected viruses lost a 
potential N-linked glycosylation site. Representative amino acid sequences of the V3 
loop for a patient that changed the viral tropism from R5 to X4-tropism and vice versa 























FIGURE 6 Amino acid sequence of the V3 loop for two patients. Patient A had an R5-tropic variant before therapy 
that changed to an X4-tropic variant under therapy. Patient B changed from an X4-tropic variant before therapy to 
an R5-tropic variant under therapy. Glycosylation sites are marked in orange, changed amino acids in the follow-
up sequence are marked in yellow. X4-tropic variants are known often to have a charged amino acid (like R) at 
positions 11 and/or 24/25, these positions are framed by a black box. Abbreviations: R5, R5-tropic HIV; X4, X4-






III.III. CART DRIVEN IMMUNE RECOVERY FAVORABLY TARGETS CXCR4-TROPIC HIV-1 
III.III.I. AIM OF THE STUDY 
In early HIV infection the majority of patients carry HIV strains with R5-tropism46. Only 
later in the disease, along with a deterioration of the immune situation, the proportion 
of X4-tropic virus isolates in the circulation starts to rise30,56,57. Reasons for this change 
in the viral preferences are not known. The previous findings on bulk sequence analysis 
identified that most patients with an X4-tropism before therapy changed to R5-tropism 
five years later, which suggests a preferential targeting of X4-tropic variants under 
therapy. The aim of this study was to monitor in detail the frequency of X4-tropic 
variants during phases of immune recovery by administration of cART through next 
generation sequencing (NGS). 
  
III.III.II. STUDY DESIGN AND SAMPLE SELECTION 
Seventy PBMC samples from 35 patients from the Swiss HIV Cohort Study prior to and 
4 years post cART initiation were included. Patients had to be in the chronic infection 
phase with low CD4 T-cell count at therapy initiation (median CD4 T-cell count 180 
cells/µL). Patients needed to present throughout undetectable virus load under therapy 
(measured quarterly) with a good CD4 T-cell response (delta CD4 T-cells above 200 
cells/µL in four years of therapy). The first line regimen consisted of a combination of at 
least three antiretroviral drugs, either three NRTIs or two NRTI combined with one or 
two protease inhibitors, or with one NNRTI. None of the patients ever received R5-
receptor antagonists for therapy. 
Tropism analysis was performed on PBMC samples with Geno2Pheno454 (Max-Planck-
Institute, Saarbrücken, Germany) on sequences obtained by a MiSeq benchtop 










III.III.III. PATIENT CHARACTERISTICS 
Thirty-five patients were included in the study with a total of 70 proviral samples. The 
patient population had a mean age of 49.6 ± 8.7 years, 68.6% were male, and 91.4% 
were white; 45.7% were MSM. Median baseline CD4 T-cell count was 180 cells/µL, and 
the median delta CD4 T-cell count was 459 cells/µL. Median viral load at baseline was 
5.1 log10 copies/mL. Four of the 35 patients (11.4%) had a delta32 heterozygous 
genotype. Baseline characteristics are summarized in TABLE 3. 
First line regiment included an NRTI backbone either with one protease inhibitor 
(n=19, 54.3%), two protease inhibitors (n=8, 22.9%), one NNRTI (n=7, 20%), or was 
exclusively NRT inhibitor based for one patient. 
 
TABLE 3 Baseline characteristics for the 35 HIV-1 infected, treatment-naïve patients. 
Data are presented as No. (%), median (min-max) values unless otherwise indicated. Abbreviations: %X4, frequency 
of X4-tropic HIV variants; SD, standard deviation; MSM, men who have sex with men; HET, heterosexual; IDU, 
injecting drug users; PBMC, peripheral blood mononuclear cells. 











Sex           
    Male 24 (68.6)   19 (67.9) 5 (71.4)   0.856 
    Female 11 (31.4)   9 (32.1) 2 (28.6)     
Age, mean years ± SD 49.6 ± 8.7   49.5 ± 8.8 50 ± 8.8   0.741 
Ethnicity           0.210 
    White 32 (91.4)   26 (92.8) 6 (85.7)    
    Black 1 (2.9)     1 (14.3)     
    Hispanic 1 (2.9)    1 (3.6)       
    Asian 1 (2.9)    1 (3.6)       
HIV transmission           0.535 
    MSM 16 (45.7)   12 (42.9) 4 (57.1)     
    HET 15 (42.9)   12 (42.9) 3 (42.9)     
    IDU 4 (11.4)    4 (14.2)       
Baseline HIV RNA load, 
    log10 copies/mL 
Baseline proviral load, 




  5.0 (4.2-6.0) 
 
3.8 (2.4-5.1) 
5.5 (5.3 -6.4) 
 
4.1 (3.7-5.5) 
  0.016 
 
0.137 
Delta CD4 T-cell count, 
    cells/µL 
459 (222-853)   434 (222-853) 463 (243-659)   0.550 
Baseline CD4 T-cell count, 
    cells/µL 
Baseline CD8 T-cell count, 










  0.174 
 
0.403 
Delta32 genotype             
    heterozygous 4 (11.4)   4 (14.3)    0.288 




III.III.IV. SAMPLE CHARACTERISTICS 
For the 70 samples the median read size was 45’833 reads per sample with a median 
variant count per sample of 354. 
At an FPR of 3.5% X4-tropic HIV-1 variants were identified in all samples except one. 
This sample contained X4-tropic variants with an FPR threshold of 5%, which is 
considered a reasonable cut-off for X4-tropic viruses using bulk sequencing. By 
applying the cut-off of 2%, as suggested by Swenson et al.63, all samples with a 
percentage of X4-tropic viruses below 2% were categorized as R5-tropic. With this rule 
40 samples (57.1%) were solely R5-tropic, and 30 (42.9%) contained at least small 
fractions of X4-tropic viruses. The determined proportion of X4-tropic viruses with NGS 
in this patient population was higher than in the previous one (p<0.001) (compare with 
TABLE 2). The mean percentage of X4-tropic variants in the 40 samples with a sole R5-
tropism assignment was 0.13% (min: 0%, max: 0.91%). This low percentage is in good 
accordance with observations by Swenson et al., suggesting that by ultra deep 
sequencing X4-tropic viruses can be found in virtually every patient63. This is important 
because only patients with a tropism test negative for X4-tropic viruses get access to 
an R5-receptor antagonist43. However, also this NGS analysis has shown that X4-tropic 
variants are present in almost all samples. In contrast the mean percentage of R5-tropic 
variants in the 30 mainly X4-tropic samples assigned as X4-tropic was 47.25% (min: 0%, 
max: 97.89%) (p≤0.001). The max value of 97.89% means that in this case the 2% cut-
off rule led to an X4-tropism assignment although 97.89% of all variants in this patient 
were R5-tropic according to the FPR. 
 
III.III.V. X4-TROPIC HIV FREQUENCY CHANGES UNDER THERAPY 
With regards to relative frequencies the proviral X4-tropic HIV-1 variants decreased or 
remained stable over time in the majority of patients (28 of the 35 patients, 80%, 
p<0.001). It increased in 7 patients (20%). For every one of these seven patients with 
an increase in the frequency of X4-tropic HIV variants (%X4) over time, one single 
provirus variant emerged in cells during suppressive therapy, and eventually became 
solely responsible for the increase in %X4. In six out of seven cases the emerging 
variant had been present as a minority already prior to therapy with a mean abundance 
of 1.95% (min: 0.02%, max: 6.99%) of the total proviral population. Only in one case 




When applying more stringent FPR thresholds 74.3% (for FPR 5%) and 71.4% (for FPR 
10%) of the patients showed decreasing or stable frequencies of proviral X4-tropic HIV-
1 variants over time. Interestingly, in patients who experienced a decline of viral X4 
populations, this reduction occurred in a slow gradual process (mean change of 
28.33%), whereas in all cases with X4 persistence the increase of X4-tropic viruses 
occurred more rapidly and towards exclusive X4 representation in the viral population 
(mean change 62.09%, p<0.001). 
The univariate analysis of the baseline characteristics, which could have an influence on 
the increase in %X4, revealed that the only associating parameter was a higher viral 
load (p=0.016) at therapy initiation for patients with an increase in %X4 (see TABLE 3). 
 
III.III.VI. ASSOCIATION WITH THE DELTA32 DELETION IN THE R5-GENE 
Thirty-one patients were homozygous for the wild type R5 gene, four patients (11.4%) 
carried a heterozygous delta32 genotype, and none was homozygous for the delta32 
mutation. The virologic outcome did not differ between these groups: All patients with 
increasing %X4 carried the wild type R5 gene (p=0.288). 
 
III.III.VII. ASSOCIATION WITH PROVIRAL DNA LOAD 
Proviral DNA loads were assessed for each sample to confirm the previously reported 
provirus decline under successful antiretroviral therapy64. In 80% of the patients in this 
study decreasing proviral loads were noted under therapy (see FIGURE 7). Furthermore, 
an increase in proviral load under therapy was not associated with a simultaneous 















FIGURE 7 HIV proviral load in copies/106 PBMC for the patient population 
before and under therapy. Abbreviations: PBMC, peripheral blood 


















III.III.VIII. MOLECULAR CHARACTERISTICS - GLYCOSYLATION PATTERNS, EVOLUTION AND DIVERSITY 
OVER TIME 
The mean percentage of the most prevalent variant of all the present variants in a 
sample was 52.7% for those samples where an X4-tropic variant was most prevalent, 
and 61.2% for samples with a most prevalent R5-tropic variant (p=0.148). 
A sample with X4-tropism assignment contained on average five viral variants with a 
frequency above 2% of the total viral population compared to four variants in the R5-
tropic samples (p=0.037). The samples with either tropism contained on average two 
variants with a frequency higher than 10% (p=0.183). In 60% of cases with an R5-
tropism the most prevalent variant did not change in the follow-up sample. This was 
different in samples with X4-tropism, for which 73.3% presented a different most 
prevalent variant in the follow-up sample (p=0.050). 
Considering only the predominant variants in samples with decreasing %X4 it was 
found that 67% of these samples did not have an N-linked glycosylation site. In 
samples with increasing %X4, 57% lacked an N-linked glycosylation site (p=0.697).  
During therapy more than half of the patients (57.1%) showed evidence for a marked 
sequence evolution in their proviruses, and in 21 patients (60%) the virus developed a 
markedly greater diversity over time and therapy. In contrast, an increase in %X4 was 
not associated with a similar increase in diversity (p=0.490) or evolution (p=0.523). 
Phylogenetic trees were used for visualizing the genetic dynamics under therapy. 




FIGURE 8 shows a representative phylogenetic tree for the patient group with decreasing 
%X4 and decreasing diversity. FIGURE 9 depicts a typical virus profile for a patient with 
an increase in %X4 that is characterized by the emergence of a single virus variant. As 
for some patients NGS data were also available for an intermediate time point (see 
chapter III.III.IX), the included bar chart in FIGURE 8 and FIGURE 9 shows the tropism 
frequency change over the years with an additional time point for the better 
understanding of the tropism dynamics over the years with therapy.  
 
III.III.IX. ANALYSIS ON EIGHT LONGITUDINALLY FOLLOWED PATIENTS 
For eight patients NGS data at three consecutive time points before therapy initiation 
and at three time points thereafter were analyzed. They were included as a control 
group to observe if an increase in %X4 before therapy can be confirmed as reported in 
literature30,56,57. In six of them (75%) the proviral load increased before therapy 
initiation. Four patients with initially R5-tropic viral variants (%X4 below 2%) had the 
same viral tropism over all follow-up time points. Three of the four patients (75%) with 














FIGURE 8 Phylogenetic trees with percentage of variant frequency before and with therapy for all present V3 
variants for a representative patient with decreasing %X4 and decreasing diversity. The green leaves represent R5-
tropic HIV-variants and the red leaves X4-tropic variants. Blue leaves represent the consensus V3 sequences of all 
subtypes, subtype A, B and C. The individual yellow leaf represents the consensus HIV-1 subtype B LTR sequence 
used for rooting. The height of the black bars indicates the frequency percentage of a variant in the whole 
sequence pool. Main variants are marked with a percentage number, colored according to their tropism. The 
variant that represents the majority under therapy is marked with a square before therapy. The separate bar chart 
represents the change in tropism frequencies counting in all variants over time. Abbreviations: V3, variable loop 3; 










FIGURE 9 Phylogenetic trees with percentage of variant frequency before and with therapy for all present V3 
variants for a representative patient with increasing %X4 and decreasing diversity. The green leaves represent R5-
tropic HIV-variants and the red leaves X4-tropic variants. Blue leaves represent the consensus V3 sequences of all 
subtypes, subtype A, B and C. The individual yellow leaf represents the consensus HIV-1 subtype B LTR sequence 
used for rooting. The height of the black bars indicates the frequency percentage of a variant in the whole 
sequence pool. Main variants are marked with a percentage number, colored according to their tropism. The 
variant that is responsible for the outgrowth is marked with a square before therapy. The separate bar chart 
represents the change in tropism frequencies counting in all variants over time. Abbreviations: V3, variable loop 3; 
LTR, long terminal repeat.  
 

































It is well established in the course of untreated disease that X4-tropic HIV-1 associates 
with disease progression30,56,57. The mechanism of how the X4-tropism contributes to 
disease progression is still not well understood, and in the context of antiretroviral 
therapy the validity of this link has not yet been demonstrated. The paper by Kaufmann 
et al. has described an impaired recovery of CD4 T-cells despite the successful 
suppression of HIV by cART61. Especially as X4-tropic viruses are known to associate 
with faster CD4 T-cell decline35 it was addressed whether a tropism determination prior 
to the initiation of cART would enable the prediction of a poorer immune recovery. 
Sixty percent of all patients with X4-tropism at therapy initiation experienced only an 
impaired recovery of CD4 T-cells (delta CD4 T-cell count below 400 cells/µL). Although 
the majority of patients with X4-tropic viruses tended to be in the incomplete 
responder group the p-value did not reach the significance level. As a possible 
confounder the lower baseline CD4 T-cell count in the incomplete responder group 
had to be considered. However, in a sub analysis both groups were significantly 
overlapping: some patients had a baseline CD4 T-cell count below 150 cells/µL but 
were still classified into the responder group, whereas some of the patients with a 
baseline CD4 T-cell count above 150 cells/µL did not reach a delta CD4 T-cell count of 
more than 400 cells/µL. 
Although X4-tropic viruses have been associated with faster CD4 T-cell loss and 
disease progression35,36, this could not be significantly associated in this patient 
population in a treated situation. This observation is in line with the data from Waters 
et al. who found that the tropism did not influence the success of therapy, although 
X4-tropism was associated with progressing CD4 T-cell loss before initiation of 
treatment35. Already in the early days of HIV tropism research, where combination 
therapy was not available, it was recognized that although X4-tropism was a predictor 
of CD4 T-cell decline it was not an indicator for a higher death risk compared to 
patients with R5-tropism65. It is still not clear how X4-tropic variants trigger a faster CD4 
T-cell depletion, but all these findings suggest that this is only happening in a 
treatment free situation. Speculating of possible reasons, one indication might be the 
reported elevated levels of T-cell activation markers (HLA-DR, CD38) in treatment- 
naïve patients with X4-tropic viruses66. 
The paper by Doitsh et al.67 has shown what can drive CD4 T-cell depletion. After 
infection of an activated cell viral transcripts are released into the cytosol. The 




transcripts and induces cell death upon pyroptosis. A mechanism characterized by 
inflammation due to the release of pro-inflammatory cytokines and other cellular 
components upon cell death. These inflammatory signals attract other CD4 T-cells on 
site that in turn can get infected.67 Therefore, higher activation levels reported in 
patients with X4-tropic viruses66 might favor a faster depletion of CD4 T-cells. In 
contrast to treatment-naïve patients, long-term infected patients on successful therapy 
show similar levels of inflammation markers such as interleukin-6 or D-dimers, 
irrespective of the viral tropism68.  
A generally faster depletion of a cell infected by X4-tropic viruses may also be caused 
by the distinct characteristics, like cell turn-over rate, of this cell population. 
Investigation of this aspect showed that T-cells infected either via R5- or X4-receptor 
have similar turn-over rates and show also no compartmentalization69. Also is the 
mentioned caspase-1 dependent mechanism of CD4 T-cell death (pyroptosis) 
independent of the viral tropism and the used receptor for infection67. As cells infected 
via X4-tropic viruses show similar characteristics to cells infected via R5-receptor, this 
aspect might be excluded as possible reason for faster CD4 T-cell depletion associated 
with X4-tropism. 
 
The subsequent comparison of the tropism before and after five years of treatment 
revealed that for the majority of patients, the tropism changed from X4-tropic to R5-
tropic during therapy. This was in contrast to viruses with R5-tropism at baseline, which 
in most cases retained their R5-tropism over time. 
The observation that the majority of patients with X4-tropic viruses at baseline changed 
to R5-tropic viruses during successful therapy was surprising, especially as it is known 
that X4-tropic variants appear later in disease and associate with rapid disease 
progression35,36. This finding argues against persisting X4-tropic viruses during therapy. 
On the contrary, it provides evidence that R5-tropic variants might have higher proviral 
stability during suppressive therapy and are therefore found more often after years of 
treatment. As the treatment effect was steady over the years, proven by the full 
suppression of the free plasma virus, other mechanisms have to influence this change 
in tropism over time. One of these managing agents might be the recovering immune 
system that acts selectively against X4-tropic viruses and/or infected cells. Support for 
this hypothesis comes from earlier reports that have demonstrated that the recognition 




elimination of a viral variant54. X4-tropic viruses are often less glycosylated than R5-
tropic viruses and might therefore be more readily recognized and eliminated by the 
host defense33,52,53,70. In turn, it has been suggested that R5-tropic viruses could have a 
significant selection advantage during chronic infection based on their evasion 
mechanism (through specific glycosylation sites) from the immune system55. Moreover 
and of critical importance, the non-pathogenic SIV in the natural host, the African 
green monkey is known to be solely R5-tropic, and these viruses are associated with an 
infection that is non-destructive for CD4 T-cells with no damage to the GALT (gut 
associated lymphoid tissue)71-73. 
Analysis on glycosylation sites revealed that in half of the cases changes to X4-tropism 
coincided with the loss of a potential N-linked glycosylation site. This is well in line with 
the finding that a progressive loss of glycosylation sites correlates with the emergence 
of X4-tropism33,53,70. Further, it was noted that in cases where the tropism changed from 
R5 to X4 only few nucleotide changes in V3 were sufficient to alter the amino acid 
sequence and obtain an X4-tropism. This can be explained by one of the used G2P 
algorithm rules that assign an X4-tropism if a charged amino acid is found at positions 
11, 24 or 25. In contrast, a tropism change from X4 to R5 required many changes in the 
V3 sequence. This observation hints that tropism changes to R5 reflect the emergence 
of an already pre-existing viral minority, as that many changes in a sequence are 
unlikely to occur as a consequence of spontaneous mutation. On the other hand, the 
changes from R5 to X4-tropism were mostly characterized by G to A transitions at 
positions 11, 24, or 25 of the V3 loop. Such G to A transitions are known to be induced 
by APOBEC3G/F (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 3G/F) 
which are part of the innate immunity of the host and act as antiviral factors74-76. It has 
also been suggested already that APOBEC3G/F might be directly responsible for or 
involved in tropism changes and the occurrence of X4-tropic variants77,78. 
 
The identified shift to R5-tropism in a majority of patients under treatment from a pre-
treatment X4-tropism, analyzed with bulk sequencing (only majority viral variant is 
detected), was subsequently confirmed when the frequencies of X4-tropic variants 
during treatment were assessed with next generation sequencing. In that part of the 
study, in the great majority of patients the percentage of X4-tropic variants decreased 
during therapy intervention, accompanied by a good CD4 T-cell response. Even 




primary outcome of the study. This indicates the solidity of the analysis. These findings 
are supported by several other studies that utilized theoretical modeling to predict that 
the initiation of cART would lead to a preferential suppression of X4-tropic variants79-81. 
Additional support comes from the MOTIVATE (Maraviroc versus Optimized Therapy in 
Viremic Antiretroviral Treatment-Experienced Patients) studies in which the R5-receptor 
antagonist maraviroc was administered to patients in salvage therapy situations. These 
patients were long-term infected, treatment experienced and the acquired resistant 
viruses allowed only for limited additional therapy options. Interestingly, the majority of 
these pre-treated patients had an R5-tropic virus at baseline, despite the fact that they 
have been infected and treated for long periods before60. After a long history of 
infection it might be expected that up to 50% of the patients will have X4-tropic 
viruses30,56,57, however, this was not the case. This has also been confirmed by another 
study, where patients under treatment and virological failure presented in the majority 
R5-tropic viruses59. 
It is therefore even more tempting to speculate that during successful treatment the 
recovering immune system might be able to preferentially target such “more visible” 
X4-tropic HIV variants or cells infected with these viruses and expressing their 
glycoproteins, which could explain the “asymmetric” reduction of X4-tropic provirus 
observed in this thesis. 
Along with the overwhelming trend of an X4 decline this study identified in a minority 
of patients the increase in X4-tropic variants. In all these cases this was characterized 
by the outgrowth of a single genetic virus variant, originating from a small minority, 
which was confirmed by NGS to have been present already prior to therapy initiation. 
Similar observations were reported by two earlier studies: Westby et al.82 had shown 
that solely X4-tropic variants emerged during application of the R5-receptor antagonist 
maraviroc. This stemmed from a pre-treatment reservoir with an ancestral background 
distinct from the main R5-tropic variants in the circulation. A case study by Verheyen et 
al. had identified an emerging X4 variant after stem cell transplantation, which again 
had emerged from a pre-existing minority variant before treatment83,84. The 
observation in all these studies that the emerging variant originated from an archived 
virus minority and that this increase was not principally associated with a greater virus 
diversity over time hints a clonal expansion of individual, infected cells in the 




a mechanism of clonal virus expansion has been demonstrated to represent the origin 
of an emerging virus85. 
The detailed evolutionary analysis of the variants in R5- and X4-tropic samples revealed 
for proviruses with assigned X4-tropism that overall the viral population had a much 
greater sequence variation. Furthermore, in over 70% of the patients molecular 
evidence suggests that a most prevalent X4-tropic variant at therapy start changed to 
an R5-tropic variant during therapy. This type of viral transformation was not observed 
where pre-treatment samples contained predominant R5-variants: In these patients 
60% of the proviral HIV sequences were preserved over time. The higher dynamics in 
X4-tropic samples with a greater number of variants overall, and a lower sequence 
conservation in the proviral pool throughout time might lend further support for the 
hypothesis that a better immunologic “visibility” and a higher immune pressure on X4-
tropic variants is critical for such “asymmetric viral dynamics and stability”. 
None of the patients in all study settings received R5-receptor antagonists. This is 
important as its administration favors the emergence of X4-tropic viruses82. 
Furthermore, the naturally occurring mutation in the CCR5 gene could also lead to a 
favorable usage of X4-tropic viruses84. The identified frequency of heterozygosis in all 
the patients did not greatly differ from the prevalence reported for the Caucasian 
population13. For the first part of the study the heterozygous patients were equally 
distributed among the responders and incomplete responders group. Overall, the 
majorities of patients in all study settings with a heterozygous mutation in the R5 gene 
had R5-tropic viruses and were not associated with an increase in the percentage of 
X4-tropic variants under therapy. The observation that also in patients with a 
heterozygous delta32 genotype %X4 declined may indicate that even the assumed 
lower surface expression of R5-receptors did not favor the X4-receptor use by the virus 
in these infections. It provides additional evidence that in the immune competent host 
the X4-tropism does not appear to be a favorable phenotype of HIV-1. This speculation 
is in full agreement with the clinical finding for patients who receive an R5-receptor 
antagonist82. For all who developed failure, the drug-driven emergence of X4-tropic 
variants immediately reverted after suspension of the R5-receptor antagonist82. 
The observed reduction of X4-tropic variants in this study is in line with some reports 
that support the decrease of X4-tropic variants after initiation of antiviral therapy79-81. In 
contrast, another study supports the emergence of X4-tropic variants in the cell 




representation of X4-tropic variants in the proviral reservoir under treatment. 
Furthermore, another study identified also a higher proportion of R5-tropic viruses in 
the cellular compartment87. However, the difference was that the authors concluded 
that based on the under-representation of X4-tropic viruses the proviral tropism testing 
system is insufficient for use87. Yet the observations of that study are in line with the 
findings here, as they also showed more R5-tropic viruses in the cellular compartment. 
The findings of this thesis have revealed that under therapy the X4-tropic HIV variants 
experience a strong downward trend in cells, even during complete viral suppression. 
This development was not expected and may even be misinterpreted in clinical 
studies87. The lower representation of X4-tropic variants is indeed real and could be 
explained best by the loss of X4-tropic infected cells during antiretroviral therapy due 
to the recovering immune system. 
The observations in this thesis strongly support the clinical concept of early treatment 
initiation and favor the early use of R5-receptor antagonists. X4-tropic variants are 
known to be rare after infection and mostly accumulate later in disease30,47,48,56,57. Along 
with this goes the observation that during failure of first line therapy most viruses 
continue to be R5-tropic59,60. Therefore, the preservation of potent immune function 
itself may contribute to suppressing or even eliminating X4-tropic virus variants. Hence, 
with initiation of early therapy the emergence of X4-tropic variants may be suppressed 
maintaining the full therapeutic potency of a regimen containing inhibitors such as 
maraviroc. Most recently the concept of early therapy initiation has received massive 
support from data of the START (Strategic Timing of Antiretroviral Therapy) trial, which 
proved that early administration of cART has great net benefits for the patient88.  
Further studies on the role of the HIV tropism during infection are needed, but 
obtained data strongly support the “Treatment as Prevention” strategy to help 




































Over the years of HIV research X4-tropic viral variants have become known as the ones 
associated with disease progression and CD4 T-cell loss in therapy free situations30,56,57. 
How the viral tropism behaves in a treated situation was not clear. This work now 
elucidates new ways of understanding how the tropism contributes to the disease 
development. The main findings of this work indicate that… 
 
…THE PRESENCE OF X4-TROPIC VIRUSES BEFORE THERAPY DOES NOT NECESSARILY LEAD TO 
AN IMPAIRED CD4 T-CELL RECOVERY UNDER TREATMENT.  
 
…PROVIRAL TROPISM CHANGES TO A PREDOMINANCE OF R5-TROPIC VIRAL VARIANTS UNDER 
THERAPY. 
 
…THE AMOUNT OF X4-TROPIC VIRAL VARIANTS GENERALLY DECREASES OR REMAINS STABLE 
UNDER THERAPY. 
 
…EMERGENCE OF X4-TROPIC VIRAL VARIANTS UNDER THERAPY CORRELATES WITH THE 
OUTGROWTH OF A SINGLE VARIANT ALREADY PRESENT AS MINORITY BEFORE THERAPY. 
 
Furthermore, X4-tropic viruses… 
 
…MIGHT BE RECOGNIZED BETTER BY THE IMMUNE SYSTEM AND COULD THEREFORE BE 
SELECTIVELY ELIMINATED BY THE IMMUNE COMPETENT HOST. 
 
…MIGHT CONTRIBUTE TO CD4 T-CELL LOSS DUE TO A HIGHER VISIBILITY, INDUCED 
INFLAMMATION, AND SELECTIVE CELL ACTIVATION. 
 
 
V.II. OUTLOOK FOR FUTURE RESEARCH TOPICS 
Further studies with larger sample sizes will be needed to clinically verify the results 
obtained in this thesis. Furthermore, the results presented here may pave the way for 
interesting additional research topics. This thesis identified that an X4-tropic variant 
increase was characterized by the outgrowth of an individual minority variant already 
present before treatment initiation. It therefore seems likely that such an outgrowth 
occurs as clonal expansion of a single cell. This could be elucidated by integration site 
analysis; if truly proliferation were responsible all proviral genomes would be 
characterized by integrating in the same position in the host genome. Furthermore, 
this analysis could reveal the genes in which HIV has integrated. Although integration is 
random, recently presented work elucidated evidence that HIV might favor integration 
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into genes involved in cell proliferation85. Another interesting question would concern 
the infected cell type responsible for an increase in X4-tropic variants. It has been 
shown that chemokine receptors are differently expressed on various cell types and 
during different stages of the disease89, also cancer might play a certain role here90. 
Maybe X4-tropic proviruses in proliferating cells can be linked to cancer and metastasis 
or to a special subset of infected T-cells, like naïve T-cells90,91. 
 
V.III. OUTLOOK FOR THE CLINICS 
The net benefit of early antiretroviral therapy has been shown in the START trial earlier 
this year88. Initiating therapy at a CD4 T-cell count higher than 500 CD4 T-cells/µL 
showed a lower risk to develop AIDS related events compared to patients that initiated 
therapy when CD4 T-cell counts were below 350 CD4 T-cells/µL 88. The findings of this 
thesis support early therapy initiation as well. The obtained results favor a decrease of 
X4-tropic viral variants during the recovery of the immune system under therapy. 
Therefore, the emergence of X4-tropic variants in a treatment free situation might be 
the consequence of the accelerated damage of the immune system. Data from the 
clinics already support this idea, as the majority of patients in a treated and failing 
regimen present R5-tropic viruses59,60. Early therapy initiation would maintain the 
potency of the immune system, thereby enabling it to control X4-tropic variants. 
Therefore, the other therapeutic target would be the R5-tropic virus that seems not to 
be readily controlled by the immune system. However, these variants have been shown 
to be efficiently reduced by the administration of the R5-receptor antagonist maraviroc 
that prohibits the infection via the R5-receptor92,93. An additional way of controlling the 
viral infection would hence include strategies to hit on both viral variants. This might be 









































Prepito NA Body Fluid Kit Chemagen 
DNA isolation and purification 
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel 
RT-PCR 
Affinity Script One-Step RT-PCR Kit Stratagene 
Standard PCR 
PfuUltra II Fusion HS DNA polymerase Agilent Technologies 
iProof™ High-Fidelity DNA polymerase Bio-Rad 
dNTPs (dATP, dCTP, dGTP, dTTP), 10mM Sigma 
illustra ExoStar 1-Step GE Healthcare 
Gel electrophoresis  
Agarose Invitrogen 
TBE buffer, 10x Amresco 
Ethidiumbromide solution (10 mg/mL) Sigma 
RedSafe™ Nucleic Acid Staining Solution Lucernachem 
Gel loading dye, blue New England Biolabs 
100 bp DNA ladder (500 μg/mL) New England Biolabs 
1 kb DNA ladder (500 μg/mL) New England Biolabs 
Glycerol anhydrous Fluka 
Sanger sequencing  
BigDye® Terminator v3.1 Applied Biosystems 














Next generation sequencing  
Agencourt AMPure XP Beckman Coulter 
Quant-iT PicoGreen dsDNA Assay Kit Invitrogen 
Nextera XT DNA Library Preparation Kit illumina 
XTrack double strand separation  






Capillary electrophoresis  
Polymer  - POP conformational analysis 
polymer 
Applied Biosystems 
Buffer 10x with EDTA Applied Biosystems 
Glycerol (87%) Fluka 
TBE buffer, 10x Amresco 
















VI.I.II. PRIMERS AND PROBES 
Nomenclature: F forward primer, R; reverse primer. The number in general (excluded 
“others” section) indicates the 5’ end on the HIV genome reference (pNL-4-3) and 
allows the calculation of the amplified PCR fragment.  
Name Sequence 5’ – 3’ 
F_6943 CAC AGT ACA ATG YAC ACA TGG AAT 
R_7365 AGT AGA AAA ATT CYC CTC YAC AAT TAA A 
F_7092 GAA TCT GTA GAA ATT AAT TGT ACA AGA C 
R_7232 TGC TCT ACT AAT GTT ACA ATG TGC TTG TCT TAT 
F_6553 ATG GGA TCA AAG CCT AAA GCC ATG TG 
R_7801 AGT GCT TCC TGC TGC TCC CAA GAA CCC AAG 
F_6848 CCA ATT CCC ATA CAT TAT TGT GCC CCG GCT GG 
R_7371 TTA CAG TAG AAA AAT TCC CCT CCA CAA TTA AA 
FAM_V3_7092_F FAM-GAA TCT GTA GAA ATT AAT TGT ACA AGA C 














GCC TCA ATA AAG CTT GCC TTG A 
GGG CGC CAC TGC TAG AGA 
FAM-CCA GAG TCA CAC AAC AGA CGG GCA CAG GTC 
TCAG-BHQ 
 
TAMRA-CCT CAG GGT CTG AGT GAA GC 
AGT TAT GCT TAG AGT GTT ATC TCC A 
GAT AGG TAC CTG GCT GTC GTC CAT 
ACC AGC CCC AAG ATG ACT ATC T 
GAA GGT GAA GGT CGG AGT C 
GAA GAT GGT GAT GGG ATT TC 









RNA and DNA extraction was performed with chemagen Prepito (Perkin Elmer, 
Baesweiler, Germany) using the NA Body Fluid Kit according to protocol. 
 
VI.II.II. PCR PREPARATION FOR BULK SEQUENCING AND XTRACK 
One-step reverse transcriptase PCR 
Reverse transcriptase was performed with Affinity Script One-Step RT-PCR Kit (Agilent 
Technologies), enabling reverse transcription and PCR in one tube. The total reaction 
volume was 50µL, containing 45µL of master mix and 5µL of patient RNA. The master 
mix included 17µL of MilliQ H2O, 25µL of Herculase II RT-PCR 2x Master Mix, 1µL of 
10µM F-6943 primer, 1µL of 10µM R-7365 primer and 1µL Affinity Script RT/RNAse 
Block. PCR reaction started with an initial step of five minutes at 45°C for reverse 
transcription and a second step at 92°C for one minute to denature the reverse 
transcriptase. Then 40 cycles of denaturing at 92°C for 20 seconds, annealing at 51°C 
for 20 seconds and elongation for 30 seconds at 68°C followed. There was a final 
elongation step for three minutes at 68°C. 
 
Nested PCR 
Reaction was performed with PFU Ultra II HF (Agilent Technologies) in a volume of 
20µL. 15µL of master mix and 5µL of patient DNA. The master mix contained 10µL of 
MilliQ H2O, 2µL of PfuUltra II Reaction Buffer, 0.5µL of dNTP, 1µL of 10µM F-7092 
primer, 1µL of 10µM R-7232 primer and 1µL PfuUltra II polymerase. PCR reaction 
started with an initial step of one minute at 92°C. Then 30 cycles of denaturing at 92°C 
for 20 seconds, annealing at 51°C for 20 seconds and elongation for 15 seconds at 
72°C followed. There was a final elongation step for three minutes at 72°C. 
For proviral DNA the first PCR was carried out with PfuUltra II with primers F-6943 and 
F-6977 under the same conditions as for the second nested PCR. 
 
VI.II.III. PCR PREPARATION FOR NEXT GENERATION SEQUENCING 
A nested PCR approach was used; both reactions were performed with PFU Ultra II HF 
(Agilent Technologies) in a volume of 20µL. 15µL of master mix and 5µL of patient 






0.5µL of dNTP, 1µL of 10µM F-6848 (1st PCR) or F-6553 (2nd PCR), 1µL of 10µM R-
7371 (1st PCR) or R-7801 (2nd PCR) and 1µL PfuUltra II polymerase. First PCR reaction 
started with an initial step of one minute at 92°C. Then one cycle of denaturing at 92°C 
for 20 seconds, annealing at 65°C for 20 seconds and elongation for 30 seconds at 
72°C followed. Afterwards one cycle of denaturing at 92°C for 20 seconds, annealing 
at 60°C for 20 seconds and elongation for 30 seconds at 72°C followed by 45 cycles of 
denaturing at 92°C for 20 seconds, annealing at 55°C for 20 seconds and elongation 
for 30 seconds at 72°C followed. A final elongation step was carried out at 72°C for 
three minutes. Condition for second nested PCR were exactly the same except for the 
annealing temperatures that were 65°C for the first cycle, 63°C for the second cycle 
and 60°C for the following 45 cycles.  
 
VI.II.IV. DNA CLEANING FOR DOWN STREAM APPLICATION 
Gel electrophoresis 
To make the PCR product visible and to validate it the DNA was loaded onto a 2% 
agarose gel containing 2g of agarose in 100µL of 1x TBE. After agarose was dissolved 
by heat and cooled down, 5µL of ethidium bromide was added. The 20µL PCR product 
was mixed with 3µL of 6x blue loading dye and loaded onto the gel. The gel was run at 
210V for 45 minutes. 
 
Gel extraction 
Gel extraction was performed according to the protocol of the NucleoSpin® Gel and 
PCR Clean-up kit (Macherey-Nagel). DNA was eluted in 35µL of elution buffer. 
 
VI.II.V. SANGER SEQUENCING 
Sequencing reaction mix contained 1µL Big Dye Terminator v3.1, 3µL Big dye 
v1.1/v1.3 Sequencing Buffer, 3µL of 1µM forward or reverse primer and 7µL of cleaned 
DNA filled up with MilliQ H2O to a final volume of 20µL. Sequencing reaction included 
40 cycles of denaturing at 96°C for 20 seconds, annealing at 50°C for 20 seconds and 
elongation for four minutes at 60°C. 
The reaction was cleaned through a Sephadex™ G-50 superfine column. The final 
cleaned PCR product was sequenced with the ABI 3130 Genetic Analyzer with a five 







VI.II.VI. NEXT GENERATION SEQUENCING 
Agencourt AMPour XP 
After PCR the DNA product was cleaned with Agencourt AMPour XP beads (Beckmann 
Coulter) according to protocol. 
 
DNA quantification 
For quantification the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen) was used 
according to protocol. 
 
Library preparation 
DNA concentration was adjusted to 0.2ng/µL and the Nextera XT DNA Library 
Preparation Kit (Illumina) was used to prepare the library according to Kit instructions. 
 
Sequencing 





The fluorescent-labeled probe was generated by labeling PCR with a fluorescent 
labeled forward primer and a biotin tagged reverse primer. The PCR was performed 
with iProof™ High-Fidelity DNA polymerase. The total reaction was performed in a 
volume of 50µL. 45µL of master mix and 5µL of 10ng/µL DNA. The master mix 
contained 31.5µL MilliQ H2O, 10µL iProof HF Buffer, 1µL of dNTP, 1µL of 10µM 
FAM_V3_7092_F primer, 1µL of 10µM Biotin_V3_7232_R primer and 0.5µL iProof™ 
polymerase. PCR was performed under the following conditions: 98°C for two minutes, 
35 cycles at 98°C for ten seconds, 48°C for 15 seconds and 72°C for ten seconds, 
followed by ten minutes at 72°C. 
The PCR product was mixed with 6x glycerol loading dye, containing 675µL anhydrous 
glycerol and 1325µL MilliQ H2O. Then it was loaded on a 2% agarose gel in 100µL 1x 
TBE and gel extracted with the NucleoSpin® Gel and PCR Clean-up kit (Macherey-
Nagel) according to protocol. DNA was eluted in 50µL elution buffer. All the steps 






For the separation of the double strand the following procedure was performed. 40µL 
of Streptavidine magnetic beads were washed three times with binding buffer 
containing 20mM Tris-HCl pH 7.5, 10mM EDTA and 2M NaCl. To the eluted DNA 50µL 
of binding buffer was added and the mixture was incubated 15 minutes with the 
washed magnetic beads in the dark. Afterwards the mixture was washed three times 
with wash buffer containing 20mM Tris-Cl pH 7.5, 10mM EDTA and 1M NaCl. The 
magnetic beads were mixed with 20µL of fresh 0.2N NaOH to separate the single 
strand. The beads were washed with 10µL of MilliQ H2O and put together with the 
20µL. 20µL of 1M Tris-HCl was added which gave a final volume of 50µL. 
 
Generation)of)molecular)weight)marker)(MWM))
The MWM was generated by labeling PCR with iProof™ High-Fidelity DNA 
polymerase. The total reaction was performed in a volume of 50µL. 45µL of master mix 
and 5µL of 10ng/µL DNA. The master mix contained 31.5µL MilliQ H2O, 10µL iProof™ 
HF Buffer, 1µL of dNTP, 1µL of 10pM/µL 2818_bcrabl primer, 1µL of 10pM/µL 
2886_revbcra primer and 0.5µL iProof™ polymerase. PCR reaction was performed 
under following conditions: 98°C for two minutes, 40 cycles at 98°C for ten seconds, 
53°C for 15 seconds and 72°C for five seconds, followed by five minutes at 72°C. 
The PCR product was mixed with 6x glycerol loading dye, containing 675µL anhydrous 
glycerol and 1325µL MilliQ H2O. Then it was loaded on a 2% agarose gel in 100µL 1x 
TBE and gel extracted with the NucleoSpin® Gel and PCR Clean-up Kit according to 
protocol. DNA was eluted in 25µL elution buffer.  
 
Generating)the)heteroduplex)
1µL of 2ng fluorescent labeled single strand probe and 7µL of patient DNA in 1x TKE 
buffer in a total volume of 10µL was denatured for five minutes at 95°C and held for 
ten minutes at 4°C. The 10µL were mixed with 5ng of molecular weight marker in 10µL 
MilliQ H2O, which gave a final volume of 20µL, which was loaded onto the ABI PRISM® 
310 Genetic Analyzer. 
 
VI.II.VIII. PROVIRAL LOAD TESTING 
Proviral loads were assessed using an in house multiplex real time PCR approach with a 
VIC labeled GAPDH probe and a FAM labeled LTR probe. 5µL of extracted patient 






primer (GAPDH), 1µL of 10µM forward primer (LTR), 1µL of 10µM reverse primer (LTR), 
0.5µL of 10µM GAPDH probe, 0.5µL of 10µM LTR probe and 10µL of 2x TaqMan® Fast 
Universal PCR Master Mix (Life Technologies) in a final volume of 20µL. The PCR 
reaction was: two minutes at 50°C, ten minutes at 95°C, 40 cycles of (15 seconds at 
95°C, one minute at 60°C). 
 
VI.II.IX. DELTA32 GENOTYPE TESTING 
The total reaction volume was 50µL, containing 45µL of master mix and 5µL of patient 
DNA. The master mix included 35.8µL of MilliQ H2O, 5µL of Taq ThermoPol Buffer 
(Bioconcept), 2µL of 10mM dNTP, 1µL of 10µM D32-forward primer, 1µL of 10µM D32-
reverse primer and 0.2µL Taq polymerase (Bioconcept). PCR reaction started with an 
initial step of five minutes at 95°C followed by 35 cycles of (95°C for five seconds, 55°C 
for ten seconds, 72°C for one minute) and a final elongation step at 72°C for two 
minutes94. 
 
VI.II.X. COMPUTATIONAL ANALYSIS 
Geno2Pheno)
Geno2Pheno was used for tropism determination based on sequence characteristics. 
For the analysis in chapters III.I. and III.II. bulk sequencing was performed and 
therefore Geno2Phenocoreceptor with a FPR cut-off of 5% was used. In chapter III.III. next 
generation sequencing was performed and the tropism determination was done with 
Geno2Pheno454 with a FPR cut-off value of 3.5%. Using next generation sequencing, an 
R5-tropism was assigned if the relative amount of X4-variants in the patient pool was 
below 2%. If the frequency of X4-variants changed by less than 1% between time 
points it was designated as “stable”. 
 
Evolutionary)analysis)and)phylogenetic)trees)
All calculations were performed with MEGA 6.0. The distance relatedness was 
calculated between the prevalent variant and all remaining variants for a sample. iTOL 










Statistical analysis were performed with R 0.97.312 and Stata 12.1. Categorical data 
were compared by means of Chi-square test, whereas continuous data were compared 
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